trending Market Intelligence /marketintelligence/en/news-insights/trending/gmd9zzwkhtpbj00mg3tw2g2 content esgSubNav
In This List

GSK vaccine receives second breakthrough therapy designation in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


GSK vaccine receives second breakthrough therapy designation in US

GlaxoSmithKline plc's meningitis B vaccine, Bexsero, received its second breakthrough therapy designation in the U.S.

The U.S. Food and Drug Administration had previously granted the designation for the prevention of the invasive meningococcal disease in individuals 10 years to 25 years old.

The new designation covers children 2 years to 10 years of age and will help expedite the development and review of the vaccine.

Meningitis B is a life-threatening bacterial infection that causes inflammation in tissues surrounding the brain and spinal cord.